Skip to main navigation
Theratechnologies Inc. Theratechnologies Inc.

    About

  • About
    • About Us
    • Board of Directors
    • Leadership Team
    • Scientific Consultants & Advisors
    • Awards
  • Medicines & Pipeline

  • Medicines & Pipeline
    • Medicines
      • Trogarzo®
      • EGRIFTA SV®
    • Pipeline & Science
      • HIV
        • F8 in HIV-Associated Excess Abdominal Fat
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Hepatology
        • Tesamorelin for the Potential Treatment of NASH
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Oncology
        • SORT1+ Technology™
        • TH1902
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Expanded Access Policy
      • Grants/ISRs/IITs
  • IR Nav

  • Investors
    • Overview
    • News, Events & Presentations
      • Press Releases
      • Company Announcements
      • Events
      • Corporate Presentations
    • Stock Information
      • Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Financial Information
      • SEC Filings
      • SEDAR Filings
      • Financial Reports
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Leadership Team
      • Committee Composition
    • Investor Resources
      • Contact IR
      • FAQs
  • Corporate Responsibility

  • Corporate Responsibility
  • Careers

  • Careers
  • Contact Us

  • Contact Us
  • en
    • en
    • fr
  • btn Alerts

  • Sign up for Email Alerts

Social icons

Bio Details

Dr. Mace Rothenberg, MD

Advisor

Mace Rothenberg

Mace L. Rothenberg, MD is a physician-executive with more than 30 years of experience across government, academia, and industry. Dr. Rothenberg recently retired from Pfizer where he served as Chief Medical Officer from 2019 to 2021.  During this time, the company initiated, completed, and obtained emergency use authorization for its COVID-19 vaccine.  Prior to that role, Mace led Clinical Development for Oncology at Pfizer from 2008 to 2018.  Over that 10 year period, his organization developed and obtained regulatory approval for 11 new cancer medicines.  Prior to joining Pfizer, Dr. Rothenberg was Professor of Medicine at Vanderbilt University and Ingram Professor of Cancer Research at the Vanderbilt-Ingram Cancer Center from 1998 to 2008.  From 1991 to 1998, Mace was Associate Professor of Medicine at the University of Texas Health Science Center at San Antonio and Executive Officer of the Southwest Oncology Group.

Dr. Rothenberg is board-certified in Internal Medicine and Medical Oncology and is a Fellow of the American College of Physicians and the American Society of Clinical Oncology. 

Dr. Rothenberg received his BA magna cum laude from the University of Pennsylvania in 1978 and his MD from the New York University School of Medicine in 1982.  He received his post-graduate training in Internal Medicine at Vanderbilt University and in Medical Oncology at the National Cancer Institute.

    Headquarters

    Theratechnologies inc.
    2015 Peel Street, 11th Floor
    Montréal, Québec
    Canada H3A 1T8
    Phone: 514 336-7800
    Fax: 514 331-9691

    European Headquarters

    Theratechnologies Europe Limited
    2 Hume Street, 4th floor
    Dublin 2
    Ireland D02 DV24
    Phone: +353 1 215 0650
    europe@theratech.com

    Investor Relations

    Elif McDonald
    Senior Director, Investor Relations
    Phone: +1-438-315-8563
    ir@theratech.com

    US Headquarters

    Theratechnologies U.S., Inc.
    101 Hudson Street
    21st Floor
    Jersey City, New Jersey 07302

    Main Nav

    • Home
    • About
    • Medicines & Pipeline
    • Investors
    • Corporate Responsibility
    • Careers
    • Contact Us
    ©2023 - Theratechnologies Inc.

    Legal Nav

    • Terms of Use
    • Privacy

    Search

    Theratechnologies